Telemark Asset Management LLC Sells 200,000 Shares of Cellebrite DI Ltd. $CLBT

Telemark Asset Management LLC reduced its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 33.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 400,000 shares of the company’s stock after selling 200,000 shares during the quarter. Telemark Asset Management LLC’s holdings in Cellebrite DI were worth $7,212,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Invesco Ltd. lifted its holdings in shares of Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after acquiring an additional 2,054,644 shares during the last quarter. Pertento Partners LLP raised its position in Cellebrite DI by 57.8% in the 3rd quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after purchasing an additional 1,702,574 shares during the period. Cooper Creek Partners Management LLC purchased a new position in Cellebrite DI in the 3rd quarter worth $55,999,000. Handelsbanken Fonder AB raised its position in Cellebrite DI by 18.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 2,900,000 shares of the company’s stock worth $53,737,000 after purchasing an additional 450,000 shares during the period. Finally, Granahan Investment Management LLC raised its position in Cellebrite DI by 1,108.5% in the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock worth $48,721,000 after purchasing an additional 2,411,726 shares during the period. 45.88% of the stock is owned by institutional investors.

Insider Activity

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 13,269 shares of company stock valued at $169,592 in the last 90 days. 5.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CLBT. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. DA Davidson began coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Needham & Company LLC decreased their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Stock Down 3.4%

Shares of NASDAQ:CLBT opened at $13.81 on Friday. The stock has a market cap of $3.44 billion, a PE ratio of 49.32, a PEG ratio of 1.71 and a beta of 1.17. The company’s fifty day moving average is $13.28 and its 200 day moving average is $15.21. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.